SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst heated debate and strong opinions regarding a recent shooting involving conservative figure Charlie Kirk. The community is actively discussing political motivations, affiliations of the suspect, and the broader implications for political discourse. This heightened attention coincides with existing volatility around the stock itself.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

The crypto $WAGMI.X is trending amid community excitement and the circulation of a new community song, fueling discussions around its potential as a leading culture coin. Many community members are rolling profits into $WAGMI.X, drawn to its active community and the sentiment that it's poised for a breakout within the meme coin cycle on the $SOL.X blockchain. Bullish sentiment is high, with many viewing it as a long-term play.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to the excitement surrounding its upcoming listing on BiFinance and a live 'Biggest Buy Contest', which the community sees as key catalysts. The community emphasizes that the project is built on organic growth and hard work, not hype, and they are rallying together to push the coin to new all-time highs. Many community members express strong conviction and encourage others to DYOR and join their Telegram group to learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

$TROLL.X is gaining attention following news of officially acquiring rights to the Trollface meme, sparking a surge in market cap and community excitement. Technical analysis suggests a bullish uptrend with potential for a breakout, as buyers actively stack and momentum builds. The community also draws comparisons to other meme coins like $SHIB.X and discusses potential for high returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease characterized by fat accumulation in the liver accompanied by inflammation and cell damage.The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes. F2 and F3 fibrosis refer to stages of liver fibrosis, with F2 indicating moderate scarring and F3 indicating severe scarring.Up to 59.1% patients enrolled in the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-impact-phase-2b">study</a> achieved MASH resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.However, the percentage of participants in the trial who achieved fibrosis improvement without worsening of MASH in an intent-to-treat analysis as compared to placebo was not statistically significant.Furthermore, only a total of 25.8% and 24.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, achieved the endpoint of both MASH resolution and fibrosis improvement, versus 13.5% in participants receiving placebo.Treatment with the drug, however, resulted in weight loss, with a mean weight loss of up to 6.2% in Pemvidutide-treated participants, compared to 1.0% in the placebo arm.Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication, the company said.Scott Harris, Chief Medical Officer of Altimmune, expressed optimism about the company holding an end-of-mid-stage trial meeting with the FDA in the fourth quarter of 2025 and rapid progression to late-stage trials following the data.Pemvidutide is an investigational drug in development for the treatment of MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol-associated Liver Disease (ALD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALT">Altimmune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_26_at_8_59_53_AM_png_cf1065258b.webp" alt="ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits" width="626" height="66"><figcaption>ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the fibrosis improvement data, which was the only thing “worth looking forward to”, was poor, and they see no ground to start a position.<stembedurl>https://stocktwits.com/Ag035/message/619068912</stembedurl>ALT stock is down by 54% this year and by 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-recalls-over-62000-silverado-trucks-in-us-over-fire-concerns/chmOVMWRR4j">General Motors Recalls Over 62,000 Silverado Trucks In US Over Fire Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.

Equity

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

Altimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line results from its 24-week Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) on Thursday.The stock climbed 7.2% on Tuesday to close at $7.71&nbsp;and extended its rally after hours with a 5.7% gain to $8.15.The upcoming readout is seen as a key milestone for the company’s lead asset, pemvidutide, a GLP-1/glucagon dual receptor agonist being evaluated across multiple liver and metabolic indications, including obesity, alcohol use disorder (AUD), and alcohol-related liver disease (ALD).<a href="https://stocktwits.com/symbol/ALT">Altimmune</a> launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options.&nbsp;The company also plans to begin a Phase 2 study in ALD later this year.Altimmune’s Chief Medical Officer, Scott Harris, previously noted that pemvidutide showed promising reductions in alcohol preference in preclinical models, suggesting potential crossover benefits for metabolic and addictive disorders.Investors will be watching closely on Thursday for signs of efficacy in liver fat reduction, inflammation, and fibrosis, which are endpoints that could position pemvidutide as a competitive candidate in the growing MASH treatment landscape.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said if the data were negative, the company might have quietly published the topline results and followed up later with a management call to explain next steps.&nbsp;<stembedurl>https://stocktwits.com/Micabella/message/619038659</stembedurl>They suggested the only potential delay could be around fibrosis data, which may require the full 48-week readout.Another trader pointed out that if the data were negative, the company might have pushed the announcement into next week’s July 4th holiday lull, when market activity is typically lower.&nbsp;<stembedurl>https://stocktwits.com/Calvary316/message/619038510</stembedurl>Releasing it this Thursday instead, they argued, gives the stock another day to run, a move they believe hints at strong results.The stock has risen 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win

Altimmune launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options. 

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape. 

Shares of Altimmune, Inc. (ALT) were in the spotlight on Tuesday morning after the company reported a narrower first-quarter (Q1) loss that was better than Wall Street expectations and secured up to $100 million in credit.Diluted net loss for the three months ended March 31, 2025, was $0.26 per share, compared to a net loss of $0.34 per share in the same period in 2024, and lower than an estimated loss of $0.34 per share, as per Finchat data.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2025-financial-results-and">company</a> ended the March quarter with cash, cash equivalents, and short-term investments totaling $150 million.Altimmune also entered into a $100 million credit facility with Hercules Capital on Tuesday, with an initial $15 million tranche funded at closing.The company said that an additional $25 million is available in 2025 at Altimmune’s option, subject to the achievement of certain clinical and financial milestones.Altimmune said the remaining $60 million will be available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to Hercules's approval. &nbsp;The company said the credit facility significantly increases Altimmune’s financial strength and flexibility.CEO Vipin K. Garg said the company is approaching a number of important milestones. In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).Altimmune also intends to commence phase 2 trials to study pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) in the second and third quarter of this year, respectively.On Stocktwits, retail sentiment around Altimmune jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_10_39_15_AM_png_8bfe41ef98.webp" alt="ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> is down by 21% this year and by over 23% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? 

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-q4-2024-earnings/chdgfF2RyA">hope</a> in the clinical-stage biotech company.The company has gained traction for its lead candidate,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-on-phase-2-obesity-drug-trial-data/c7zs1ZqRP8">pemvidutide</a>, a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH. In a mid-stage trial, the drug showed that it helped patients reduce their weight by more than 15%.&nbsp;At its R&amp;D Day last week, Altimmune provided more cheer as it unveiled plans to test pemvidutide for treating alcohol use disorder and alcohol-associated liver disease in the second and third quarters of this year.According to The Fly, Evercore ISI said it likes Altimmune's latest expansion and suggested that pemvidutide could rake in more revenue for the new goals than MASH, as 35 million people in the U.S. alone suffer from alcohol use disorder and alcohol-associated liver disease.The research firm added that there is some preclinical and anecdotal evidence to support its thesis.Assuming all goes well, Altimmune will need to fund a Phase 3 program later this year in addition to the AUD/ALD studies, said Evercore, which has an Outperform rating on the shares and a price target of $25.Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. Last year's key&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">C-suite hire</a> at a "pivotal time" for Altimmune bolstered their belief.A Betaville&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.msn.com/en-us/money/companies/altimmune-soars-amid-takeover-speculation/ar-AA1AWioc">report</a> suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms — one FTSE-100 listed, one German, and one U.S.-based — may be involved.<figure class="image"><img style="aspect-ratio:1320/710;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_Stocktwits_poll_on_March_18_png_3a31e58347.webp" alt="ALT Stocktwits poll on March 18.png" width="1320" height="710"><figcaption>ALT Stocktwits poll on March 18. | source: Stocktwits</figcaption></figure>One bullish user said it's "not if, but when [a deal happens]. Too much TAM [total addressable market] for this pipeline of a molecule."<stembedurl>https://stocktwits.com/artiebet/message/608157454</stembedurl>Another user speculated a buyout could happen "within three months," noting the stock is "heading north each week" with "higher lows, higher highs."<stembedurl>https://stocktwits.com/LiveNow1225/message/608159514</stembedurl>Altimmune's stock, which was&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Altimmune Shares Sink In 2025, But Retail Traders Are Optimistic About A Buyout

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended gains in after-hours trading. Retail buzz on Stocktwits surged, hitting a three-month high.The clinical-stage biopharma company reported a net loss of $23.2 million, or $0.33 per share, for Q4 2024 — an improvement from a $31.6 million loss ($0.54 per share) a year ago.&nbsp;Altimmune ended the year with $132 million in cash and investments, which it expects to fund operations well into the second half of 2026, covering key milestones, including the Phase 2b readout for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) next quarter.CEO Vipin K. Garg said the IMPACT trial was one of "the fastest enrolling biopsy-driven Phase 2b MASH trials, reflecting pemvidutide's appeal due to its potent reduction of liver fat and body weight.""We are confident it will achieve statistically significant improvements in both MASH resolution and fibrosis at trial readout."Altimmune also said it had secured FDA clearance for two additional indications submitted under Investigational New Drug (IND) applications in Q4, with Phase 2 efficacy studies set to begin mid-2025. The company plans to unveil details at its virtual R&amp;D Day on March 13.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume soaring 273% in the 24 hours leading to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_sentiment_and_message_volume_Feb_27_1ee28571fe.png" alt="ALT sentiment and message volume Feb 27.png" width="1316" height="316"><figcaption>ALT sentiment and message volume Feb 27 | source: Stocktwits</figcaption></figure>One user predicted a sharp rally to $50, interpreting comments from Altimmune's chief scientific officer that pemvidutide "is the best drug for many indications."<stembedurl>https://stocktwits.com/romanaround/message/606129604</stembedurl>Another speculated on the new INDs, saying they could be for dyslipidemia (or hypertriglyceridemia) and Cirrhosis.<stembedurl>https://stocktwits.com/Cryptobearcat/message/606145193</stembedurl>Altimmune's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH.&nbsp;The stock drew attention in December after being <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI).Shares of Altimmune are down over 12% year-to-date.&nbsp;According to Koyfin data, eight of the nine analysts covering the stock rate it a 'Buy' or 'Strong Buy,' while one has a 'Hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

Shares of Altimmune, Inc. climbed early on Thursday, recovering from a nearly 6% drop in the previous session, drawing significant retail attention.&nbsp;The stock became one of the top three trending symbols on Stocktwits during early trading after the company announced its inclusion in the Nasdaq Biotechnology Index ($NBI) starting Dec. 23.<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">Altimmune</a>, a clinical-stage biotech firm, is currently developing pemvidutide for obesity and metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;CEO Vipin Garg said, “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company.”“With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year,” he added.The Nasdaq Biotechnology Index, established in 1993, tracks the performance of Nasdaq-listed biotech and pharmaceutical companies that meet strict criteria such as market capitalization, trading volume, and seasoning requirements.&nbsp;The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.On Stocktwits, retail sentiment for Altimmune shifted from ‘neutral’ to ‘extremely bullish,’ accompanied by a sharp rise in message volume.&nbsp;<stembedurl>https://stocktwits.com/romanaround/message/597152901</stembedurl><stembedurl>https://stocktwits.com/Designed2Gain/message/597160936</stembedurl>A poll on the platform revealed that 52% of retail investors believe the NBI addition will provide a significant long-term boost to the stock, while 22% expect minimal impact.<a href="https://stocktwits.com/symbol/ALT">Altimmune’s shares</a> got a boost last month following better-than-expected quarterly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-q3-loss-narrows/cJ40TqmROm">earnings</a> and positive updates on pemvidutide.&nbsp;The company reported a successful FDA meeting that finalized its Phase 3 obesity program design, with no major safety concerns raised.&nbsp;Analysts like H.C. Wainwright’s Patrick Trucchio have expressed confidence in the drug’s differentiation within the GLP-1 agonist space, citing robust efficacy attributes and a well-defined clinical program.Still, Altimmune’s stock remains down nearly 30% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Nasdaq company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer

'Mad Money' host Jim Cramer weighs in on stock including: Ford, Rigetti Computing, LyondellBasell, Altimmune, and AST SpaceMobile...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.27	--	--	N/A
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT
Q4 '24	-$0.33	-$0.33	0.75%	BEAT
Q3 '24	-$0.36	-$0.32	10.40%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ALT News

ALT Altimmune Inc